利伐沙班市场：依适应症、剂型、病患类型、通路和地区划分

2025 年全球利伐沙班市场规模估计为 1,790 万美元，预计 2032 年将达到 2,830 万美元，2025 年至 2032 年的复合年增长率为 6.8%。

数字。 2025 年利伐沙班各地区市场占有率（%）

过去十年，受全球深层静脉栓塞症和肺动脉栓塞盛行率不断上升的推动，利伐沙班的全球市场稳步成长。利伐沙班是一种口服抗凝血剂，可作为血液凝固途径中Xa因子的抑制剂。对于需要抗凝血治疗的患者，利伐沙班可作为Warfarin的替代品。此药最常用于降低非瓣膜性心房颤动患者发生中风和全身性栓塞的风险，治疗深层静脉栓塞症和肺动脉栓塞，以及预防復发性静脉血栓栓塞症。随着人们对新型口服抗凝血药物益处的认识不断提高以及患有目标疾病的患者数量不断增加，利伐沙班市场预计将在未来几年继续快速扩张。

市场动态

全球利伐沙班市场的成长是由于老年人口的增加，他们更容易发生血栓性栓塞症，人们对新型口服抗凝血剂的偏好日益增加，而非Warfarin等传统药物，以及世界各地实施的外科手术数量不断增加。然而，与学名药相比，利伐沙班治疗的成本较高，这是限制其广泛使用的主要因素。从积极的一面来看，评估利伐沙班用于更多适应症的临床试验正在进行中，而新年龄组的核准有望创造新的机会。此外，开发适合特定患者类型的改良剂型可以克服高成本带来的挑战。

研究的主要特点

• 本报告对全球利伐沙班市场进行了详细分析，并以 2024 年为基准年，展示了预测期（2025-2032 年）的市场规模和年复合成长率（CAGR%）。
• 它还强调了各个领域的潜在商机并说明了该市场的有吸引力的投资提案矩阵。
• 它还提供了关于市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景以及主要企业采用的竞争策略的主要考察。
• 它根据公司亮点、产品系列、关键亮点、财务表现和策略等参数，介绍了全球利伐沙班市场的主要企业概况。
• 本报告的见解将使负责人和公司经营团队能够就未来的产品发布、类型升级、市场扩张和行销策略做出明智的决策。
• 全球利伐沙班市场报告针对该行业的各个相关人员，例如投资者、供应商、产品製造商、经销商、新进业者和金融分析师。
• 相关人员将透过分析全球利伐沙班市场所使用的各种策略矩阵更轻鬆地做出决策。

目录

第一章 调查目的与前提条件

• 研究目标
• 先决条件
• 简称

第二章 市场展望

• 报告描述
  • 市场定义和范围
• 执行摘要

第三章市场动态、法规与趋势分析

• 市场动态
• 影响分析
• 监管情景
• 产品发布/核准
• PEST分析
• 波特分析
• 併购情景

4. 2025 年至 2032 年全球Rivaroxaban市场（依适应症划分）（百万美元）

• 介绍
• 心房颤动
• 深层静脉栓塞症（DVT）
• 肺动脉栓塞（PE）
• 预防静脉血栓栓塞症(VTE)
• 其他（急性冠状动脉症候群等）

5. 2025-2032 年全球Rivaroxaban市场（以剂型划分）（百万美元）

• 介绍
• 锭剂
• 暂停

6. 2025-2032 年全球利伐沙班市场按病患类型划分（百万美元）

• 介绍
• 成人
• 孩子们

7. 2025-2032 年全球利伐沙班市场按分销管道划分（百万美元）

• 介绍
• 医院和诊所
• 零售药局
• 网路药局

第 8 章 2020-2032 年全球利伐沙班市场，按地区划分，金额（百万美元）

• 介绍
• 北美洲
• 美国
• 加拿大
• 拉丁美洲
• 巴西
• 阿根廷
• 墨西哥
• 其他拉丁美洲国家
• 欧洲
• 德国
• 英国
• 西班牙
• 法国
• 义大利
• 俄罗斯
• 其他欧洲国家
• 亚太地区
• 中国
• 印度
• 日本
• 澳洲
• 韩国
• 东南亚国协
• 其他亚太地区
• 中东
• 海湾合作委员会国家
• 以色列
• 其他中东地区
• 非洲
• 南非
• 北非
• 中部非洲

第九章 竞争格局

• Bayer AG
• Janssen Pharmaceuticals, Inc.
• Interquim SA
• Natco Pharma
• Mylan NV
• 山德士（诺华旗下的一个部门）
• Teva Pharmaceutical Industries Ltd.
• Aurobindo Pharma
• Zydus Cadila
• Apotex Inc.
• Hetero Labs Limited
• Fresenius Kabi AG
• Sun Pharmaceutical Industries Ltd.
• Lupin Pharmaceuticals
• Reddy's Laboratories
• Bristol-Myers Squibb
• Merck & Co., Inc.
• Pfizer Inc.
• Eisai Co., Ltd.
• Amgen Inc.

第 10 章分析师建议

• 兴衰
• 一致的机会地图

第 11 章 参考文献与调查方法

• 参考
• 调查方法
• 关于出版商

Global Rivaroxaban Market is estimated to be valued at USD 17.9 Mn in 2025 and is expected to reach USD 28.3 Mn by 2032, growing at a compound annual growth rate (CAGR) of 6.8% from 2025 to 2032.

Figure. Rivaroxaban Market Share (%), By Region 2025

The global Rivaroxaban market has been growing steadily over the past decade on the back of rising prevalence of deep vein thrombosis and pulmonary embolism disorders globally. Rivaroxaban is an oral anticoagulant that acts as an inhibitor of factor Xa in the blood coagulation pathway. It has emerged as a preferred alternative to warfarin for patients requiring anticoagulation therapy due to advantages such as fixed dosing without need for frequent monitoring. The drug is most commonly used to reduce risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation, treat deep vein thrombosis and pulmonary embolism, and reduce recurrence of venous thromboembolism. With growing awareness about benefits of novel oral anticoagulants and increasing patient pool affected by target diseases, the rivaroxaban market is anticipated to continue expanding rapidly over the coming years.

Market Dynamics:

The global rivaroxaban market growth is driven by rising geriatric population who are more prone to thromboembolic disorders, growing preference for novel oral anticoagulants over traditional drugs like warfarin, and increasing number of surgical procedures performed worldwide. However, high costs associated with rivaroxaban therapy compared to generic drugs is a major factor limiting its widespread adoption. On the positive side, ongoing clinical trials evaluating rivaroxaban for additional indications and approval for new age groups are expected to create new opportunities. Moreover, development of modified dosage forms suited for specific patient types could help overcome challenges posed by high costs.

Key features of the study:

• This report provides in-depth analysis of the global rivaroxaban market, and provides market size (USD Million) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global rivaroxaban market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Johnson & Johnson, Pfizer, Bayer, and Sanofi
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global rivaroxaban market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global rivaroxaban market.

Detailed Segmentation:

• By Indication Insights (Revenue, USD Mn, 2020 - 2032)
  • Atrial Fibrillation
  • Deep Vein Thrombosis (DVT)
  • Pulmonary Embolism (PE)
  • Prophylaxis of Venous Thromboembolism (VTE)
  • Others (Acute Coronary Syndrome, etc.)
• By Formulation Insights (Revenue, USD Mn, 2020 - 2032)
  • Tablets
  • Suspension
• By Patient Type Insights (Revenue, USD Mn, 2020 - 2032)
  • Adults
  • Pediatrics
• By Distribution Channel Insights (Revenue, USD Mn, 2020 - 2032)
  • Hospitals and Clinics
  • Retail Pharmacies
  • Online Pharmacies
• By Regional Insights (Revenue, USD Mn, 2020 - 2032)
  • North America
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
  • Africa
  • South Africa
  • North Africa
  • Central Africa
• Key Players Insights
  • Bayer AG
  • Janssen Pharmaceuticals, Inc.
  • Interquim SA
  • Natco Pharma
  • Mylan N.V.
  • Sandoz (a Novartis division)
  • Teva Pharmaceutical Industries Ltd.
  • Aurobindo Pharma
  • Zydus Cadila
  • Apotex Inc.
  • Hetero Labs Limited
  • Fresenius Kabi AG
  • Sun Pharmaceutical Industries Ltd.
  • Lupin Pharmaceuticals
  • Reddy's Laboratories
  • Bristol-Myers Squibb
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Eisai Co., Ltd.
  • Amgen Inc.

Table of Contents

1. RESEARCH OBJECTIVES AND ASSUMPTIONS

• Research Objectives
• Assumptions
• Abbreviations

2. MARKET PURVIEW

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Global Rivaroxaban Market, By Indication
  • Global Rivaroxaban Market, By Formulation
  • Global Rivaroxaban Market, By Patient Type
  • Global Rivaroxaban Market, By Distribution Channel
  • Global Rivaroxaban Market, By Region

3. MARKET DYNAMICS, REGULATIONS, AND TRENDS ANALYSIS

• Market Dynamics
• Impact Analysis
• Key Highlights
• Regulatory Scenario
• Product Launches/Approvals
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario

4. Global Rivaroxaban Market, By Indication, 2025-2032, (USD Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Atrial Fibrillation
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Deep Vein Thrombosis (DVT)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Pulmonary Embolism (PE)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Prophylaxis of Venous Thromboembolism (VTE)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Others (Acute Coronary Syndrome, etc.)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

5. Global Rivaroxaban Market, By Formulation, 2025-2032, (USD Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2020 - 2032
  • Segment Trends
• Tablets
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Suspension
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

6. Global Rivaroxaban Market, By Patient Type, 2025-2032, (USD Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2020 - 2032
  • Segment Trends
• Adults
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Pediatrics
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

7. Global Rivaroxaban Market, By Distribution Channel, 2025-2032, (USD Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2020 - 2032
  • Segment Trends
• Hospitals and Clinics
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

8. Global Rivaroxaban Market, By Region, 2020 - 2032, Value (USD Mn)

• Introduction
  • Market Share (%) Analysis, 2025,2028 & 2032, Value (USD Mn)
  • Market Y-o-Y Growth Analysis (%), 2020 - 2032, Value (USD Mn)
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Formulation, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Patient Type, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Mn)
• U.S.
• Canada
• Latin America
  • Introduction
  • Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Formulation, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Patient Type, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Mn)
• Brazil
• Argentina
• Mexico
• Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Formulation, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Patient Type, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Mn)
• Germany
• U.K.
• Spain
• France
• Italy
• Russia
• Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Formulation, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Patient Type, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Mn)
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Formulation, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Patient Type, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Mn)
• GCC Countries
• Israel
• Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Formulation, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Patient Type, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Mn)
• South Africa
• North Africa
• Central Africa

9. COMPETITIVE LANDSCAPE

• Bayer AG
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Janssen Pharmaceuticals, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Interquim SA
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Natco Pharma
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Mylan N.V.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Sandoz (a Novartis division)
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Teva Pharmaceutical Industries Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Aurobindo Pharma
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Zydus Cadila
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Apotex Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Hetero Labs Limited
• Fresenius Kabi AG
• Sun Pharmaceutical Industries Ltd.
• Lupin Pharmaceuticals
• Reddy's Laboratories
• Bristol-Myers Squibb
• Merck & Co., Inc.
• Pfizer Inc.
• Eisai Co., Ltd.
• Amgen Inc.

10. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

11. References and Research Methodology

• References
• Research Methodology
• About us